In another twist to the tale of Starboard Value's push for change at Pfizer, the activist investor has claimed former executives Ian Read and Frank D'Amelio were bullied into lending their
Two former Pfizer executives drawn into a campaign by activist investor Starboard Value to shake up the company have withdrawn their support for the plan.
The week has started with reports that activist investor Starboard Value has amassed a $1 billion stake in pharma group Pfizer and wants strategic changes to restore growth.
Pfizer is voluntarily withdrawing its sickle cell disease (SCD) therapy Oxbryta from all world markets after finding an "imbalance" in deaths in its clinical trials programme.
Pfizer's anti-GDF-15 antibody ponsegromab was able to achieve weight gain in cancer patients with cachexia – a life-threatening metabolic syndrome caused by the underlying disease with no a
Vaxcyte's new pneumococcal vaccine may only have phase 1/2 results behind it, but analysts are already predicting it could be a major competitor to rival shots from Pfizer and MSD.